Markus Diener and colleagues (July 12, p 142) 1 might believe that the study protocol and sample size account for the confl icting fi ndings in the PROUD trial 1 (not showing a prophylactic effect of triclosancoated sutures against surgical site infection [SSI]) and for findings from smaller randomised controlled trials [2] [3] [4] that show benefits for use in antibiotic sutures in prevention of SSI. However, the discrepancy might be more because of differences in baseline characteristics of participants.
Antimicrobial eff ects of triclosancoated sutures seem to depend on the length of skin incision, extent of wound contamination at operation, and concurrent diseases amenable to infections, such as diabetes. This is the fi rst recognised outbreak in the west Africa region; the communities are not familiar with Ebola virus. Health beliefs, cultural practices, and human behaviour have combined to fan the dispersal of the disease. The concerns of the west African people, the myths, and conspiracies need to be heard and understood before communities will sufficiently engage to reduce further spread.
Civil unrest is a feature of this humanitarian disaster; suspicion and aggression towards health workers is widespread. 2 The US and British military are indeed best resourced to build field hospitals; but their arrival is being seen on the ground, by some, as an invasion. These fears need to be addressed.
The socioeconomic collapse of the worst affected countries, already causing food insecurity, 3 could exacerbate the destructive effects of Ebola, and create violence. The delivery of effective infection control measures and health care will be challenging under the threat of regional conflict. 4 This humanitarian disaster will deepen in spite of committed eff orts of governments, unless we can understand and address the human beliefs and behaviours fuelling this crisis.
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diseases. It will also enable quick follow-up trials of combinations of antivirals and new treatments that have already shown evidence of activity. A diff erent type of RCT might also become an option once more than one drug has shown effi cacyeven efficacy in animal models. Then, patients could ethically be randomised to one investigational drug or another. No-one would get only standard care.
We accept that RCTs can generate strong evidence in ordinary circumstances; not, however, in the midst of the worst Ebola epidemic in history. The urgent need is to establish whether new investigational drugs off er survival benefi ts, and thus which, if any, should be recommended by WHO to save lives. We have innovative but proven trial designs for doing exactly that. We should be using them, rather than doggedly insisting on gold standards that were developed for diff erent settings and purposes.
